Bach‐Yen Nguyen

6.5k citations

25 papers · 4.2k indexed · 2 hit papers · h-index 20

Co-authors: Joseph J. Eron Jeffrey Chodakewitz Kathleen Squires Jon C. Cook Scott M. Hammer John Phair Lisa M. Demeter Michael D. Hughes
Topics: HIV/AIDS drug development and treatment (22 papers)HIV Research and Treatment (18 papers)HIV/AIDS Research and Interventions (12 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: New England Journal of Medicine Annals of Internal Medicine Hepatology
Partner nations: United States France Germany

In The Last Decade

Bach‐Yen Nguyen

25 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 2.1k citations Scott M. Hammer, Kathleen Squires et al. New England Journal of Medicine profile →
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

2015 386 citations Reem Ghalib, Deborah D. Brown et al. profile →

Peers

Countries citing papers authored by Bach‐Yen Nguyen

Since Specialization

Citations

This map shows the geographic impact of Bach‐Yen Nguyen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bach‐Yen Nguyen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bach‐Yen Nguyen more than expected).

Fields of papers citing papers by Bach‐Yen Nguyen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bach‐Yen Nguyen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bach‐Yen Nguyen. The network helps show where Bach‐Yen Nguyen may publish in the future.

Co-authorship network of co-authors of Bach‐Yen Nguyen

This figure shows the co-authorship network connecting the top 25 collaborators of Bach‐Yen Nguyen. A scholar is included among the top collaborators of Bach‐Yen Nguyen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bach‐Yen Nguyen. Bach‐Yen Nguyen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season 2019 ·Drug Safety ·Gaël Dos Santos,Bach‐Yen Nguyen,Silvia Damaso,Lode Godderis,Xavier Martínez‐Gómez,(unknown),(unknown),Ignacio Salamanca de la Cueva,(unknown),Alexander C. Schmidt,Anne Yeakey	8
2	Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials 2018 ·The American Journal of Gastroenterology ·Philippe J. Zamor,John M. Vierling,Reem Ghalib,Velimir A. Luketic,Natarajan Ravendhran,Luis A. Balart,Michael Robertson,Peggy Hwang,George J. Hanna,Bach‐Yen Nguyen,Eliav Barr,Rohit Talwani,Brian L. Pearlman	2
3	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial 2018 ·Clinical Infectious Diseases ·Chloe Orkin,Kathleen Squires,Jean‐Michel Molina,Paul E. Sax,Wing-Wai Wong,Otto Sussmann,Richard Kaplan,Lisa Lupinacci,Anthony Rodgers,Xia Xu,Gina Lin,Sushma Kumar,Peter Sklar,Bach‐Yen Nguyen,George J. Hanna,Carey Hwang,Elizabeth A. Martin,(unknown)	107
4	Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection 2017 ·Hepatology Communications ·Nancy Reau,Michael Robertson,Hwa-ping Feng,Luzelena Caro,Wendy W. Yeh,Bach‐Yen Nguyen,Janice Wahl,Eliav Barr,Peggy Hwang,Stephanie O. Klopfer	9
5	Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection 2014 ·Antiviral Therapy ·Joseph J. Eron,David A. Cooper,Roy T. Steigbigel,Bonaventura Clotet,Patrick Yéni,Kim M. Strohmaier,Anthony Rodgers,Richard J. O. Barnard,Bach‐Yen Nguyen,Hedy Teppler,(unknown)	8
6	Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jürgen K. Rockstroh,Edwin DeJesus,Jeffrey L. Lennox,Yazdan Yazdanpanah,Michael S. Saag,Hong Wan,Anthony Rodgers,(unknown),Michael D. Miller,Mark J. DiNubile,Bach‐Yen Nguyen,Hedy Teppler,Randi Y. Leavitt,Peter Sklar	167
7	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK 2012 ·HIV Clinical Trials ·Edwin DeJesus,Jürgen K. Rockstroh,Jeffrey L. Lennox,Michael S. Saag,Adriano Lazzarin,Jing Zhao,Hong Wan,Anthony Rodgers,(unknown),Michael D. Miller,Mark J. DiNubile,Bach‐Yen Nguyen,Hedy Teppler,Randi Y. Leavitt,Peter Sklar,(unknown)	26
8	A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results 2012 ·HIV Clinical Trials ·Michael J. Kozal,Sergio Lupo,Edwin DeJesus,Jean‐Michel Molina,Cheryl McDonald,François Raffi,Jorge Benetucci,Marco Mancini,Rong Yang,Victoria Wirtz,(unknown),Jenny Zhang,Li Zhu,Dilek Arikan,Awny Farajallah,Bach‐Yen Nguyen,Randi Y. Leavitt,Donnie McGrath,Max Lataillade,(unknown)	70
9	Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection 2012 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Eduardo Gotuzzo,Martin Markowitz,Winai Ratanasuwan,Graham Smith,(unknown),Javier O Morales-Ramirez,Kim M. Strohmaier,Chengxing Lu,(unknown),Bach‐Yen Nguyen,Hedy Teppler	19
10	Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients 2012 ·Antimicrobial Agents and Chemotherapy ·Matthew L. Rizk,Yaming Hang,Wen‐Lin Luo,Jing Su,Jing Zhao,Havilland Campbell,Bach‐Yen Nguyen,Peter Sklar,Joseph J. Eron,Larissa Wenning	77
11	Long-Term Safety from the Raltegravir Clinical Development Program 2011 ·Current HIV Research ·Hedy Teppler,Deborah D. Brown,Randi Y. Leavitt,Peter Sklar,Hong Wan,Xia Xu,Fabio Lievano,(unknown),T. Christopher Mast,Bach‐Yen Nguyen	30
12	Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies 2011 ·AIDS ·Jürgen K. Rockstroh,Hedy Teppler,Jing Zhao,Peter Sklar,Michael D. Miller,Charlotte M. Harvey,Kim M. Strohmaier,Randi Y. Leavitt,Bach‐Yen Nguyen	23
13	Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium 2011 ·Annals of the New York Academy of Sciences ·Bach‐Yen Nguyen,Robin Isaacs,Hedy Teppler,Randi Y. Leavitt,Peter Sklar,Marian Iwamoto,Larissa Wenning,Michael D. Miller,Joshua Chen,(unknown),Wei Xu,Robert A. Fromtling,Joseph P. Vacca,Steven D. Young,Michael Rowley,(unknown),Keith Gottesdiener,Daria J. Hazuda	41
14	Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Martin Markowitz,Bach‐Yen Nguyen,Eduardo Gotuzzo,Fernando Mendo,Winai Ratanasuwan,Colin Kovacs,(unknown),Javier O Morales-Ramirez,Clyde S. Crumpacker,Robin Isaacs,Havilland Campbell,Kim M. Strohmaier,Hong Wan,Robert M. Danovich,Hedy Teppler	94
15	Effects of Omeprazole on Plasma Levels of Raltegravir 2009 ·Clinical Infectious Diseases ·Marian Iwamoto,Larissa Wenning,Bach‐Yen Nguyen,Hedy Teppler,(unknown),Rand R. Rhodes,William D. Hanley,Bo Jin,Charlotte M. Harvey,Sheila Breidinger,Neal Azrolan,Hayley Farmer,Robin Isaacs,(unknown),Julie A. Stone,John A. Wagner	69
16	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase 2007 ·AIDS ·John M. Murray,Sean Emery,Anthony D. Kelleher,Matthew Law,Joshua Chen,Daria J. Hazuda,Bach‐Yen Nguyen,Hedy Teppler,David A. Cooper	151
17	Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection 2007 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Martin Markowitz,Bach‐Yen Nguyen,Eduardo Gotuzzo,Fernando Mendo,Winai Ratanasuwan,Colin Kovacs,(unknown),Javier O Morales-Ramirez,Clyde S. Crumpacker,Robin Isaacs,Lucinda R. Gilde,Hong Wan,Michael D. Miller,Larissa Wenning,Hedy Teppler	317
18	Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Martin Markowitz,Javier O Morales-Ramirez,Bach‐Yen Nguyen,Colin Kovacs,Roy T. Steigbigel,David A. Cooper,(unknown),Robert A. Schwartz,Robin Isaacs,Lucinda R. Gilde,Larissa Wenning,Jing Zhao,Hedy Teppler	293
19	Long‐term Virologic and Immunologic Responses in Human Immunodeficiency Virus Type 1–Infected Children Treated with Indinavir, Zidovudine, and Lamivudine 2001 ·The Journal of Infectious Diseases ·Shirley Jankelevich,Brigitta U. Mueller,Crystal L. Mackall,Sharon L. Smith,Sheryl Zwerski,Lauren V. Wood,Steven L. Zeichner,Leslie Serchuck,Seth M. Steinberg,Robert P. Nelson,John W. Sleasman,Bach‐Yen Nguyen,Philip A. Pizzo,Robert Yarchoan	25
20	A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Lessbreakdown → 1997 ·New England Journal of Medicine ·Scott M. Hammer,Kathleen Squires,Michael D. Hughes,(unknown),Lisa M. Demeter,Judith S. Currier,Joseph J. Eron,Judith Feinberg,Henry H. Balfour,Lawrence Deyton,Jeffrey Chodakewitz,Margaret A. Fischl,John Phair,Louise Pedneault,Bach‐Yen Nguyen,Jon C. Cook	2125

About Bach‐Yen Nguyen

Bach‐Yen Nguyen is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 25 papers that have together received 4.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (12 papers). The work is most often cited by research in Virology (2.9k citations), Infectious Diseases (3.4k citations) and Hepatology (654 citations). Bach‐Yen Nguyen has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Joseph J. Eron, Jeffrey Chodakewitz, Kathleen Squires, Jon C. Cook, Scott M. Hammer, John Phair, Lisa M. Demeter, Michael D. Hughes, Judith Feinberg and Henry H. Balfour. Their work appears in journals such as New England Journal of Medicine, Annals of Internal Medicine and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact